Avalo Therapeutics, Inc. (AVTX) SEC Filings & Earnings Calls

Clinical development risk

“Avalo is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.”

Financing risk

“we expect that our existing cash and cash equivalents and investments are sufficient to fund operations for at least twelve months from the filing date” · word for word

Dilution risk

“To the extent that we raise capital through the sale of equity, the ownership interest of our existing stockholders will be diluted” · word for word

Clinical development risk: Phase 3 program for abdakibart not yet initiated; regulatory and trial execution risks.

“Plans to initiate registrational Phase 3 program in H1 2027; no guarantee of success.”

Operating loss trend: increasing net loss may pressure cash runway if not managed.

“Net loss increased $15.6M YoY to $36.4M in Q2 2026.”

Potential dilution from increased beneficial ownership cap for preferred investor.

“Removal of restriction allowing investor to increase beneficial ownership from 4.99% to 9.99% of common stock.”

Enhanced executive severance may increase cash outflow in change-of-control scenarios.

“Amended employment agreements provide up to 1.5x base salary plus target bonus and equity acceleration upon change-in-control termination.”

Clinical trial risk: Phase 3 program may fail to replicate Phase 2 results.

“Phase 2 LOTUS trial positive but Phase 3 registrational program not yet initiated; no guarantee of success.”

Dilution risk: $431.3M equity offering significantly increases share count.

“Completed public offering of common stock and pre-funded warrants for gross proceeds of $431.3 million; weighted average shares increased 91% YoY.”

Clinical trial failure risk

“The Company is a clinical stage biotechnology company...has incurred significant operating losses and negative cash flows from our operations.”

Dilution risk

“To the extent that we raise capital through the sale of equity, the ownership interest of our existing stockholders will be diluted.” · word for word

Dependence on single asset

“Our lead asset, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody ('mAb').” · word for word

Dilution risk: 19.73M shares and 1.4M warrants issued, significantly increasing share count.

“Offering of 19,730,000 shares of common stock and pre-funded warrants to purchase up to 1,400,000 shares.”

Clinical trial risk: Phase 3 program may fail to replicate Phase 2 results.

“Phase 2 results positive but Phase 3 registrational program not yet initiated; no guarantee of success.”

Reduced milestone liability improves financial flexibility.

“Milestone buyout option reduces potential future liability from $15M to $5.125M.”

Clinical trial failure risk for PSUs

“The performance metric for the PSU Awards is based on the timing of data release and efficacy of the Company’s Phase 2 LOTUS trial, and the achieved units may range from 0% to 150% of the target number depending on the level of achievement against the specified performance metric.” · word for word

High cash burn / net loss trajectory

“Net Loss (thousands) 2025: $(78,259) vs 2024: $(35,129) vs 2023: $(31,544)”

Clinical trial risk: Phase 2 LOTUS trial results pending; failure could impact pipeline value.

“Topline data expected in Q2 2026; no guarantee of positive results.”

Cash burn: Net cash used in operating activities $51.5M in FY2025; runway into 2028 but dependent on trial outcomes.

“Net cash used in operating activities was $51.5 million for the year ended December 31, 2025.” · word for word

Single-asset dependency

“Our focus and reliance on abdakibart (AVTX-009) increases the risk of such exposure.” · word for word

Patent cliff

“Our US composition-of-matter patent for abdakibart (AVTX-009) expired in February 2026.” · word for word

Clinical trial failure

“If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to to complete, the development and commercialization of our product candidates.” · word for word

Capital need

“We expect to require additional capital in the future to continue to fund our operations and to finance the further advancement of our product candidates, which might not be available to us on acceptable terms, or at all.” · word for word

Regulatory approval uncertainty

“The marketing approval processes of the United States Food and Drug Administration (the "FDA") and other regulatory authorities are lengthy, time‑consuming, costly and inherently unpredictable.” · word for word

Clinical trial risk for AVTX-009

“Phase 2 LOTUS trial results expected Q2 2026; failure could impact pipeline.”

Clinical trial risk: AVTX-009 Phase 2 data expected mid-2026; failure could impair pipeline value.

“Topline data expected in mid-2026; no approved products.”

No product revenue; dependent on successful development and commercialization.

“Product revenue, net was $0 for Q3 2025.”

Derivative liability of $23.2M non-current; potential dilution from warrants.

“Derivative liability, non-current of $23,160 thousand as of September 30, 2025.”

No Product Revenue

“Total revenues, net ... $0 ... $249 for the three months ended September 30, 2025 and 2024, respectively.”

Derivative Liability Volatility

“Change in fair value of derivative liability ... $ (12,530) ... $ (1,100) for the three months ended September 30, 2025 and 2024, respectively.” · word for word

Cash Burn and Financing Dependency

“For the nine months ended September 30, 2025, Avalo generated a net loss of $64.5 million and negative cash flows from operations of $37.2 million.” · word for word

Clinical Trial Risk

“Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa.” · word for word

Clinical trial risk; no data or results disclosed yet.

“Phase 2 trial enrollment completed; no efficacy or safety data provided.”